CA2326623A1 - Gene codant pour une proteine interagissant avec une syntaxine - Google Patents

Gene codant pour une proteine interagissant avec une syntaxine Download PDF

Info

Publication number
CA2326623A1
CA2326623A1 CA002326623A CA2326623A CA2326623A1 CA 2326623 A1 CA2326623 A1 CA 2326623A1 CA 002326623 A CA002326623 A CA 002326623A CA 2326623 A CA2326623 A CA 2326623A CA 2326623 A1 CA2326623 A1 CA 2326623A1
Authority
CA
Canada
Prior art keywords
synip
rna
cells
dna sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326623A
Other languages
English (en)
Inventor
Jing Min
Jeffrey Eugene Pessin
Alan Robert Saltiel
Li-Jyun Syu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2326623A1 publication Critical patent/CA2326623A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux gènes et des polypeptides dérivés codant pour une protéine interagissant avec une syntaxine. L'invention concerne également des vecteurs et des cellules hôtes comprenant ce nouveau gène, ainsi que des procédés d'utilisation du nouveau gène, des polypeptides et des anticorps ciblant spécifiquement les polypeptides dérivés de ces nouveaux gènes. Ces procédés permettent la détection de déficiences génétiques, la localisation sous-cellulaire du polypeptide, l'isolement de classes distinctes d'ARN, l'application de thérapies géniques, les diagnostics pour les syndromes faisant intervenir la résistance à l'insuline, la mise au point de stratégies de criblage de spécialités pour des inhibiteurs de la protéine interagissant avec la syntaxine.
CA002326623A 1998-04-20 1999-04-19 Gene codant pour une proteine interagissant avec une syntaxine Abandoned CA2326623A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8245498P 1998-04-20 1998-04-20
US60/082,454 1998-04-20
PCT/US1999/008568 WO1999054465A2 (fr) 1998-04-20 1999-04-19 Gene codant pour une proteine interagissant avec une syntaxine

Publications (1)

Publication Number Publication Date
CA2326623A1 true CA2326623A1 (fr) 1999-10-28

Family

ID=22171326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326623A Abandoned CA2326623A1 (fr) 1998-04-20 1999-04-19 Gene codant pour une proteine interagissant avec une syntaxine

Country Status (9)

Country Link
EP (1) EP1071771A2 (fr)
JP (1) JP2002512031A (fr)
KR (1) KR20010042834A (fr)
AU (1) AU769825B2 (fr)
BR (1) BR9909732A (fr)
CA (1) CA2326623A1 (fr)
NZ (2) NZ526016A (fr)
WO (1) WO1999054465A2 (fr)
ZA (1) ZA200005845B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503756B1 (en) * 2000-09-22 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of syntaxin 4 interacting protein expression
AU2003297062A1 (en) * 2002-12-11 2004-06-30 University Of Massachusetts METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
FR2890859B1 (fr) * 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6891098A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)

Also Published As

Publication number Publication date
WO1999054465A2 (fr) 1999-10-28
AU3653599A (en) 1999-11-08
NZ526016A (en) 2004-10-29
JP2002512031A (ja) 2002-04-23
ZA200005845B (en) 2002-04-19
BR9909732A (pt) 2000-12-19
WO1999054465A9 (fr) 2000-01-27
KR20010042834A (ko) 2001-05-25
EP1071771A2 (fr) 2001-01-31
WO1999054465A3 (fr) 2000-03-02
NZ507640A (en) 2003-12-19
AU769825B2 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AU700915B2 (en) Lung cancer marker
JP3294575B2 (ja) Ｉｇｆ−１レセプターと相互作用するタンパク質、それをコードする遺伝子及びそれらの使用
EP1005549A2 (fr) Polypeptides de tumeur de la prostate et compositions antigenes
WO1995014777A1 (fr) Polypeptides fixant la p53 et polynucleotides les codant
US5717067A (en) Substrate for the epidermal growth factor receptor kinase
WO2000052173A2 (fr) Homologues de sphingosine kinase humaine clones
AU769825B2 (en) Gene encoding syntaxin interacting protein
CA2236154A1 (fr) Nouvel isoforme creba
US6596855B2 (en) Probes for chondrogenesis
US20020086384A1 (en) Splice variants of oncogenes
US6680196B1 (en) Gene that is amplified and overexpressed in cancer and methods of use thereof
EP0863204B1 (fr) Cycline i humaine et gene la codant
AU2003266470A1 (en) Gene encoding syntaxin interacting protein
MXPA00009332A (es) Gen que codifica la proteina sintaxina interactuante
CA2359145A1 (fr) Proteine de voies d'exocytose et leurs procedes d'utilisation
US6300473B1 (en) SLM-1: a novel Sam68-like mammalian protein
US20070015155A1 (en) Novel protein usable in screening drug improving type 2 diabetes
EP1135496B1 (fr) Ucp5
US7342102B2 (en) Uncoupling protein 5 (UCP5)
WO1997043415A9 (fr) Facteur de liaison de la cycline de type d et emplois dudit produit
WO1997043415A1 (fr) Facteur de liaison de la cycline de type d et emplois dudit produit
JP2002101891A (ja) 細胞周期調節タンパク質
JP2000093178A (ja) Ｄｄ１３遺伝子

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead